We had previously reported that relaxin down-regulated S100A4 in MDA-MB-231 and in a stable MDA/RLN2 transfectant, thus, identifying S100A4 as a novel target gene for relaxin in breast cancer cells [26]. Here, S100A4 is linked to breast cancer.